Clinical Study of WT2725 in Patients With Advanced Malignancies
Completed · Phase 1
Conditions studied: Cancer
In brief
This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1
Key facts
- Study ID
- NCT01621542
- Run by
- Sumitomo Pharma America, Inc.
- People needed
- 64
- Starts
- 2012-07-31
- Expected to finish
- 2017-05-17
- Last updated by the study team
- 2019-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The University of Arizona Cancer Center - North Campus — Tucson, Arizona, United States
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- The University of Chicago Medical Center — Chicago, Illinois, United States
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- The University of Texas, MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.